JLE

European Journal of Dermatology

MENU

Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast Volume 30, issue 2, March-April 2020

Figures


  • Figure 1
Authors
1 Department of Dermatology, Aichi Medical University, Aichi, Japan
2 Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan

Pembrolizumab is an anti-PD-1 antibody approved for cancer therapy, facilitating anticancer immunity via the PD-1/PD-1L axis. The immune-related adverse effects (IrAE) of pembrolizumab include induction or exacerbation of psoriasis [1-3]. Herein, we report a case of pembrolizumab-induced psoriasis vulgaris, also known as plaque-like psoriasis, that was successfully treated with apremilast.A 74-year-old man suffering from bladder cancer visited our department presenting with exanthema. He had been [...]